@article{3128880,
    title = "Azacitidine in a patient with newly diagnosed acute myeloid leukemia and poor risk cytogenetics: Outcomes of prolonged therapy",
    author = "Pappa, V. and Girkas, K. and Sambani, C. and Pagageorgiou, S. and Tsirigiotis, P. and Karvounis, K. and Stathopoulou, E. and Economopoulos, T. and Dimitriadis, G. and Dervenoulas, I.",
    journal = "Leukemia Research",
    year = "2012",
    volume = "36",
    number = "4",
    pages = "e78-e80",
    issn = "0145-2126",
    doi = "10.1016/j.leukres.2011.11.022",
    keywords = "azacitidine;  hemoglobin, acute granulocytic leukemia;  aged;  blood toxicity;  bone marrow biopsy;  cancer patient;  case report;  Caucasian;  cytogenetics;  erythrocyte transfusion;  female;  hemoglobin blood level;  human;  injection site reaction;  karyotype 46,XX;  karyotyping;  laboratory test;  letter;  leukocyte count;  long term care;  multiple cycle treatment;  myelodysplastic syndrome;  neutrophil count;  patient referral;  priority journal;  thrombocyte count;  treatment outcome, Abnormal Karyotype;  Aged;  Antimetabolites, Antineoplastic;  Azacitidine;  Female;  Follow-Up Studies;  Humans;  Leukemia, Myeloid, Acute;  Randomized Controlled Trials as Topic;  Risk;  Treatment Outcome"
}